JP2013515745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515745A5 JP2013515745A5 JP2012546245A JP2012546245A JP2013515745A5 JP 2013515745 A5 JP2013515745 A5 JP 2013515745A5 JP 2012546245 A JP2012546245 A JP 2012546245A JP 2012546245 A JP2012546245 A JP 2012546245A JP 2013515745 A5 JP2013515745 A5 JP 2013515745A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition according
- amino acids
- amino acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 137
- 150000001413 amino acids Chemical class 0.000 claims description 80
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 108090000663 Annexin A1 Proteins 0.000 claims description 7
- 102100040006 Annexin A1 Human genes 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 239000002078 nanoshell Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 102000000412 Annexin Human genes 0.000 claims 1
- 108050008874 Annexin Proteins 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- -1 binding tag Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28983309P | 2009-12-23 | 2009-12-23 | |
| US61/289,833 | 2009-12-23 | ||
| PCT/US2010/062072 WO2011079304A1 (en) | 2009-12-23 | 2010-12-23 | Methods and compositions related to annexin 1-binding compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015051656A Division JP6331030B2 (ja) | 2009-12-23 | 2015-03-16 | アネキシン１結合化合物に関する方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013515745A JP2013515745A (ja) | 2013-05-09 |
| JP2013515745A5 true JP2013515745A5 (enExample) | 2013-12-12 |
| JP6184101B2 JP6184101B2 (ja) | 2017-08-23 |
Family
ID=43923683
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012546245A Active JP6184101B2 (ja) | 2009-12-23 | 2010-12-23 | アネキシン１結合化合物に関する方法および組成物 |
| JP2015051656A Active JP6331030B2 (ja) | 2009-12-23 | 2015-03-16 | アネキシン１結合化合物に関する方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015051656A Active JP6331030B2 (ja) | 2009-12-23 | 2015-03-16 | アネキシン１結合化合物に関する方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9610359B2 (enExample) |
| EP (1) | EP2515944B1 (enExample) |
| JP (2) | JP6184101B2 (enExample) |
| CA (1) | CA2784645C (enExample) |
| SG (2) | SG181899A1 (enExample) |
| WO (1) | WO2011079304A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10030036B2 (en) * | 2009-05-15 | 2018-07-24 | Lahjavida, Llc | Method and dyes for detecting and destroying cancer cells |
| CN102898527B (zh) | 2011-07-25 | 2016-12-21 | 三星电子株式会社 | 融合蛋白、药物组合物及预防或治疗癌症的方法 |
| FI3468621T3 (fi) * | 2016-06-10 | 2023-01-13 | Anneksiinien ydindomeeni ja sen käyttöjä antigeenin kuljettamisessa ja rokottamisessa | |
| KR102422174B1 (ko) * | 2016-08-16 | 2022-07-18 | 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 | 악성 종양 표적 펩티드 |
| US20200030452A1 (en) * | 2016-09-30 | 2020-01-30 | IF7Cure, Inc. | Process for the Manufacture of a Tumor-Vasculature Targeting Antitumor Agent |
| WO2018146820A1 (ja) | 2017-02-09 | 2018-08-16 | 株式会社Ｃｉｃｓ | 計測装置及び計測プローブ |
| JP6613499B2 (ja) * | 2017-08-24 | 2019-12-04 | 学校法人藤田学園 | 細胞殺傷剤 |
| SG11202006539RA (en) * | 2018-01-09 | 2020-08-28 | Fujita Acad | Cytocidal agent |
| CN112512577B (zh) * | 2018-05-17 | 2025-11-04 | 韩亦苹 | 结直肠癌的治疗、预防和预后检测的方法 |
| JP7440914B2 (ja) * | 2018-06-20 | 2024-02-29 | 国立大学法人弘前大学 | ホウ素中性子捕捉療法用の腫瘍組織を短時間で選択的ないし局所的に標的化できる集積性ボロン１０薬剤 |
| JP7224628B2 (ja) * | 2019-02-01 | 2023-02-20 | 国立研究開発法人産業技術総合研究所 | 抗ｍｃ１６抗体 |
| US12109276B2 (en) | 2019-03-15 | 2024-10-08 | Lahjavida, Llc | Near-infrared dyes and conjugates for targeting tumors |
| EP3946631A1 (en) * | 2019-03-26 | 2022-02-09 | Shimadzu Corporation | Photoimmunotherapy and pharmaceutical agent used therefor |
| CN111120645B (zh) * | 2019-12-30 | 2021-10-08 | 潍柴动力股份有限公司 | 一种挡位控制方法、装置及电子设备 |
| US12370266B2 (en) | 2022-09-13 | 2025-07-29 | Core Quantum, Inc. | Polymer composite nanomaterial encapsulation system |
| CN116199748B (zh) * | 2023-01-16 | 2025-08-05 | 中国地质大学（武汉） | 多肽荧光探针及其在检测活细胞内聚集蛋白中的应用 |
| CN116606351B (zh) * | 2023-04-17 | 2025-04-18 | 合肥师范学院 | 一种基于理性分子设计构建的抗菌肽hsp-m4及制备方法和应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1016978B (de) | 1955-05-16 | 1957-10-03 | Iashellia Res Ltd | Mittel zur Bekaempfung des Pflanzenwachstums |
| CH588887A5 (enExample) | 1974-07-19 | 1977-06-15 | Battelle Memorial Institute | |
| JPS5186117A (en) | 1975-01-27 | 1976-07-28 | Tanabe Seiyaku Co | Johoseibiryushiseizainoseiho |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4418052A (en) | 1980-08-12 | 1983-11-29 | Wong Dennis W | Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4761288A (en) | 1984-09-24 | 1988-08-02 | Mezei Associates Limited | Multiphase liposomal drug delivery system |
| US5628936A (en) | 1987-03-13 | 1997-05-13 | Micro-Pak, Inc. | Hybrid paucilamellar lipid vesicles |
| US5474848A (en) | 1987-03-13 | 1995-12-12 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US4853228A (en) | 1987-07-28 | 1989-08-01 | Micro-Pak, Inc. | Method of manufacturing unilamellar lipid vesicles |
| US5011686A (en) | 1987-09-21 | 1991-04-30 | Creative Biomolecules, Inc. | Thrombus specific conjugates |
| US5013497A (en) | 1988-03-03 | 1991-05-07 | Micro-Pak, Inc. | Method and apparatus for producing lipid vesicles |
| US5024829A (en) | 1988-11-21 | 1991-06-18 | Centocor, Inc. | Method of imaging coronary thrombi |
| US5643873A (en) | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
| CA2163860A1 (en) | 1993-06-30 | 1995-01-12 | Chung C. Hsu | Method for preparing liposomes |
| US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US5897945A (en) | 1996-02-26 | 1999-04-27 | President And Fellows Of Harvard College | Metal oxide nanorods |
| US6506564B1 (en) | 1996-07-29 | 2003-01-14 | Nanosphere, Inc. | Nanoparticles having oligonucleotides attached thereto and uses therefor |
| GB9708265D0 (en) | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
| HUP0103283A3 (en) | 1998-06-11 | 2002-05-28 | Dimensional Pharm Inc | Pyrazinone protease inhibitors, pharmaceutical compositions containing them and use of the compounds |
| US6451969B1 (en) * | 1999-01-15 | 2002-09-17 | The Burnham Institute | Methods for inhibiting tumor metastasis, and peptides useful therfor |
| US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US6530944B2 (en) | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
| US20040037775A1 (en) * | 2000-08-01 | 2004-02-26 | Siahaan Teruna J. | Leukocyte internalized peptide-drug conjugates |
| JP2004524281A (ja) | 2000-11-30 | 2004-08-12 | ザ ペン ステート リサーチ ファウンデイション | Ｄｎａメチルトランスフェラーゼ阻害剤 |
| US7220827B2 (en) * | 2002-09-27 | 2007-05-22 | Nihon Medi-Physics Co., Ltd. | Compound binding to leukocytes and medicinal composition containing the compound in labeled state as the active ingredient |
-
2010
- 2010-12-23 US US13/515,930 patent/US9610359B2/en active Active
- 2010-12-23 CA CA2784645A patent/CA2784645C/en active Active
- 2010-12-23 EP EP10803326.7A patent/EP2515944B1/en active Active
- 2010-12-23 WO PCT/US2010/062072 patent/WO2011079304A1/en not_active Ceased
- 2010-12-23 SG SG2012046652A patent/SG181899A1/en unknown
- 2010-12-23 SG SG10201704812TA patent/SG10201704812TA/en unknown
- 2010-12-23 JP JP2012546245A patent/JP6184101B2/ja active Active
-
2015
- 2015-03-16 JP JP2015051656A patent/JP6331030B2/ja active Active
-
2017
- 2017-04-04 US US15/478,699 patent/US20170326245A1/en not_active Abandoned
-
2021
- 2021-04-26 US US17/240,714 patent/US20210260202A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013515745A5 (enExample) | ||
| JP2018503668A5 (enExample) | ||
| JP2013513377A5 (enExample) | ||
| JP2017523781A5 (enExample) | ||
| JP2015522264A5 (enExample) | ||
| WO2011157713A3 (en) | Cell-penetrating peptides and uses therof | |
| JP2012255007A5 (enExample) | ||
| EP2574623A3 (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
| Sadeqzadeh et al. | Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells | |
| JP2014526881A5 (enExample) | ||
| WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
| CA2994279A1 (en) | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same | |
| CN105188728A (zh) | 用于肾靶向的肽和肽-活性物质-缀合物 | |
| JP2019534884A5 (enExample) | ||
| JP2016531583A5 (enExample) | ||
| JP2019524871A5 (enExample) | ||
| JP2009533317A5 (enExample) | ||
| JP2019537600A5 (enExample) | ||
| JP2019537562A5 (enExample) | ||
| WO2016168578A1 (en) | siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER | |
| Mollaei et al. | A brief review of exosomes and their roles in cancer | |
| JP2023503797A (ja) | 分子ガイドシステムペプチド及びその使用 | |
| CN108578369A (zh) | 表面双修饰的靶向人血清白蛋白纳米药物载体的制备与应用 | |
| Ying et al. | Recent advances and strategies in tumor vasculature targeted nano-drug delivery systems | |
| Pechar et al. | Polymer cancerostatics targeted with an antibody fragment bound via a coiled coil motif: In vivo therapeutic efficacy against murine BCL1 leukemia |